ArticleHaematologica2022

It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies.

Caroline BessonPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.